These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 27890494)

  • 1. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.
    Hendifar AE; Marchevsky AM; Tuli R
    J Thorac Oncol; 2017 Mar; 12(3):425-436. PubMed ID: 27890494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
    Wolin EM
    Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.
    Wolin EM
    Oncologist; 2015 Oct; 20(10):1123-31. PubMed ID: 26306904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
    Swarts DR; Ramaekers FC; Speel EJ
    Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
    Langfort R; Rudziński P; Burakowska B
    Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.
    Hilal T
    Ther Adv Med Oncol; 2017 Mar; 9(3):189-199. PubMed ID: 28344664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and treatment of the neuroendocrine tumors of the lung].
    Gálffy G
    Magy Onkol; 2018 Jul; 62(2):113-118. PubMed ID: 30027939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and management of typical and atypical lung carcinoids.
    Pusceddu S; Lo Russo G; Macerelli M; Proto C; Vitali M; Signorelli D; Ganzinelli M; Scanagatta P; Duranti L; Trama A; Buzzoni R; Pelosi G; Pastorino U; de Braud F; Garassino MC
    Crit Rev Oncol Hematol; 2016 Apr; 100():167-76. PubMed ID: 26917456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
    Prinzi N; Rossi RE; Proto C; Leuzzi G; Raimondi A; Torchio M; Milione M; Corti F; Colombo E; Prisciandaro M; Cascella T; Spreafico C; Beninato T; Coppa J; Lo Russo G; Di Bartolomeo M; de Braud F; Pusceddu S
    Clin Lung Cancer; 2021 May; 22(3):161-169. PubMed ID: 33618994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of pulmonary neuroendocrine tumors.
    Ramirez RA; Chauhan A; Gimenez J; Thomas KEH; Kokodis I; Voros BA
    Rev Endocr Metab Disord; 2017 Dec; 18(4):433-442. PubMed ID: 28868578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.
    Koumarianou A; Filosso PL; Bodei L; Castano JP; Fernandez-Cuesta L; Deroose CM; Foll M; Dromain C; Reed NS; Caplin M; Capdevila J; Falkerby J; Faggiano A; Frilling A; Grande E; Hicks RJ; Kasajima A; Kos-Kudla B; Krishna BA; Lim E; Rinke A; Singh S; Thirlwell C; Volante M; Walter T
    J Neuroendocrinol; 2024 Aug; 36(8):e13412. PubMed ID: 38754956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines.
    Gosain R; Mukherjee S; Yendamuri SS; Iyer R
    Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30545054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pulmonary neuroendocrine neoplasms].
    Sayeg Y; Sayeg M; Baum RP; Kulkarni HR; Presselt N; Mäder I; Kunze A; Sänger J; Hörsch D; Bonnet R
    Pneumologie; 2014 Jul; 68(7):456-77. PubMed ID: 25006841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.
    Hörsch D; Schmid KW; Anlauf M; Darwiche K; Denecke T; Baum RP; Spitzweg C; Grohé C; Presselt N; Stremmel C; Heigener DF; Serke M; Kegel T; Pavel M; Waller CF; Deppermann KM; Arnold R; Huber RM; Weber MM; Hoffmann H
    Oncol Res Treat; 2014; 37(5):266-76. PubMed ID: 24853787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus).
    Phan AT; Oberg K; Choi J; Harrison LH; Hassan MM; Strosberg JR; Krenning EP; Kocha W; Woltering EA; Maples WJ;
    Pancreas; 2010 Aug; 39(6):784-98. PubMed ID: 20664476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung.
    Hanley KZ; Dureau ZJ; Cohen C; Shin DM; Owonikoko TK; Sica GL
    Cancer Cytopathol; 2018 Apr; 126(4):236-242. PubMed ID: 29316326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in neuroendocrine tumours of the lung: a single-centre experience.
    Filosso PL; Ruffini E; Di Gangi S; Guerrera F; Bora G; Ciccone G; Galassi C; Solidoro P; Lyberis P; Oliaro A; Sandri A
    Eur J Cardiothorac Surg; 2014 Mar; 45(3):521-6; discussion 526. PubMed ID: 24092506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent updates on grading and classification of neuroendocrine tumors.
    Kim JY; Hong SM; Ro JY
    Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroendocrine tumors of the lung].
    Takei H; Asamura H
    Nihon Rinsho; 2004 May; 62(5):877-82. PubMed ID: 15148812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
    Rose DB; Nellesen D; Neary MP; Cai B
    J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.